Jeremy Stuart SC.D, MPH, PhD

Dr. Jeremy Stuart graduated from the University of Minnesota with a B.S in Genetics and Cell Biology, where he was subsequently awarded a Regents’ scholarship and obtained an MPH in Toxicology. He then went on to earn his doctorate in Genetics and Complex Diseases at Harvard University, where he was awarded the prestigious Ruth L. Kirschstein Training Grant. He completed his post-doc fellowship at the Harvard School of Public Health, where he studied the effects of adipose tissue on the growth of tumor cells using three dimensional cell culture models. Jeremy was recruited to join Agencourt Personal Genomics, were he became a core developer of the SOLiD next-generation sequencing technology. After APG was acquired by Applied Biosystems, Jeremy served as a Senior Project Coordinator, advising commercial, clinical, and product development strategies around next-generation sequencing at leading institutions. Jeremy has published works in a number of leading scientific journals and holds several patents in the next-generation sequencing space. As a scientific adviser and applications scientist, Jeremy enabled the adoption of high throughput sequencing at prominent institutions such as Memorial Sloan-Kettering Cancer Center and the Broad Institute. Jeremy was part of the senior management team that completed a management buyout of Lab21 Ltd’s US operations to co-found Selah Genomics. In April 2014, a publicly traded British firm, EKF Diagnostics, acquired Selah Genomics and retained Jeremy in his current role.